VCYT
VERACYTE, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 3 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Apr 8
- May 5 ▲ Veracyte reported Q1 2026 earnings with total revenue of $139.1M (+2…
- May 20 to May 22 ▼ 2 days of insider sells: $1.5M by 2 insiders, avg $44.99
- Jun 4 ▼ 4 insiders sell $8.0M at $50.10
- Jun 18 ▼ 1 insider sell $197.2K at $52.89
- Jun 30 ▲ 4 funds open new positions (13F)
- Sep 1 to Sep 4 ▼ 2 days of insider sells: $942.1K by 4 insiders, avg $43.06
- Sep 14 to Sep 24 ▼ 3 days of insider sells: $717.8K by 2 insiders, avg $43.47
- Oct 19 ▼ 1 insider sell $81.5K at $43.70
- Oct 27 ▼ 2 insiders sell $1.1M at $50.00
- Nov 4 ▲ Earnings: VCYT Q3 2026 Earnings: EPS $0.51 (+21.8% vs est)
- Nov 5 ▼ Leerink Partners downgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
10 insiders sold $12.7M.
- InstitutionsBULLISH
Q2 2026: 31 added (4 new), 16 trimmed or exited. Largest new: Driehaus Capital Management $61.4M, Artemis Investment Management $37.5M.
- AnalystsBULLISH
16 of 18 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −2.7% to 9.56M shares. 8.2 days to cover, ≈11.8% of shares.
- TrendDOWNTREND
43% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 26.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | $96.5M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | $84.1M |
| MORGAN STANLEY | ADD | $70.0M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | $61.4M |
| Sumitomo Mitsui Trust Group, Inc. | TRIM | $45.2M |
| Point72 Asset Management, L.P. | ADD | $43.3M |
| Artemis Investment Management LLP | NEW | $37.5M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $31.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +77%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Stephens & Co. MAINTAIN | Overweight |
| Nov 10, 2026 | Piper Sandler MAINTAIN | Overweight |
| Nov 10, 2026 | Freedom Capital Markets MAINTAIN | Buy |
| Nov 9, 2026 | UBS MAINTAIN | Buy |
| Nov 5, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Nov 5, 2026 | Needham MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Wygant Jonathan VP, Chief Accounting Officer Oct 28, 2026 | TAX W/H | $65.7K |
Holstein Jens Director Oct 27, 2026 | SELL | $375.0K |
EASTHAM KARIN Director Oct 27, 2026 | EXERCISE | $270.1K |
Holstein Jens Director Oct 27, 2026 | EXERCISE | $264.8K |
EASTHAM KARIN Director Oct 27, 2026 | SELL | $742.6K |
Bhanji Muna Director Oct 19, 2026 | SELL | $81.5K |
Holstein Jens Director Sep 24, 2026 | SELL | $352.5K |
Holstein Jens Director Sep 24, 2026 | EXERCISE | $264.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $1.57 | $1.44–$1.86 | -19.5% | $634.3M |
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 1 press release · 3 bullish · 2 bearish · 16 neutral- NEUTRAL SC 13G/ANov 12, 2026
Artisan Partners Limited Partnership filed an amended Schedule 13G reporting a 2.9% passive stake…
Artisan's 2.9% stake is below the 5% threshold that would require a 13D filing, confirming a passive posture. The reduction from the prior 7.7% stake (filed by Fidelity, a different filer) is not…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting a 7.7% passive stake in Veracyte as of…
Fidelity's increased passive stake to 7.7% is a routine update and does not signal activist intent. Monitor for any future conversion to a 13D filing, which would indicate a shift to active…
- NEUTRAL 8-KNov 4, 2026
Veracyte reported Q3 2026 revenue of $151.8M (+15% YoY), slightly above the $147.2M consensus, and…
Monitor Decipher Prostate volume trends and the impact of Convergent Genomics acquisition on bladder cancer testing revenue. The narrowed guidance and flat non-GAAP EPS YoY suggest limited near-term…
- NEUTRAL INST-CLUSTEROct 30, 2026
Congress Asset Management initiated a $90M position in Veracyte during 2026-Q3, accounting for…
The cluster is driven by a single large active manager initiation. Without insider buying or additional institutional corroboration, the signal is weak. Monitor next 13F filing for Congress Asset…
All VCYT filing & press-release reports (22)
- SC 13G/A reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportOct 30, 2026
- CLUSTER reportOct 28, 2026
- CLUSTER reportOct 28, 2026
- 144 reportOct 27, 2026
- 144 reportOct 27, 2026
- CLUSTER reportSep 22, 2026
- PRESS-RELEASE reportSep 14, 2026
- CLUSTER reportSep 4, 2026
- 144 reportJun 18, 2026
- CLUSTER reportJun 4, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportMay 27, 2026
- 144 reportMay 20, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 22, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 4, 2026
- 8-K reportFeb 25, 2026